AstraZeneca today finalised an agreement with Thailand’s Department of Disease Control to supply 257,500 doses of the long-acting antibody (LAAB) combination (tixagevimab and cilgavimab) AZD7442, aimed at protecting immunocompromised individuals from developing symptomatic COVID-19, with the first delivery scheduled for within the third quarter this year.